FDA's container closure draft maps packaging information across eleven dossier sections

In August 2026 FDA published the draft guidance Container Closure Systems for Human Drugs and Biological Products (Docket FDA-2026-D-7957), and asked for comments by 13 October 2026. It is draft guidance: its recommendations are nonbinding and it is marked as not for implementation. When final, it will supersede the May 1999 guidance on the same subject and the 2002 questions and answers that went with it. Until then, the 1999 guidance remains FDA's current thinking.

Most commentary has focused on the science: a risk-based framework built on five factors (safety of packaging materials, protection, performance, the effects of the manufacturing process, and storage and handling), a more structured role for extractables and leachables, and container closure integrity as a lifecycle question. Those changes matter to the people who test packaging. For the people who write the dossier, the most useful page is near the end.

Eleven sections, three kinds of information

Section VI of the draft sets out what should be submitted in each type of application. Its Table 4 lists the eCTD locations for container closure information in a marketing application, and it covers more than one system. For drug-substance packaging, the table points to 2.3.S.6, 3.2.S.6 and 3.2.S.7. For drug-product packaging, it points to 2.3.P.7, 3.2.P.2.4, 3.2.P.2.5, 3.2.P.3.5, 3.2.P.7 and 3.2.P.8. The toxicological assessment of extractables and leachables goes to 2.6.6.8 and 4.2.3.7.7.

For the drug product alone, that is six sections drawing on what, in the laboratory, is one set of components and one body of test data. The material of construction is identified in 3.2.P.7. Its compatibility and leachables assessment sit in 3.2.P.2.4. Integrity testing for a sterile product sits in 3.2.P.2.5. Cleaning, depyrogenation and sterilisation of the components sit in 3.2.P.3.5. Stability sits in 3.2.P.8. The safety argument for the leachables found sits with the nonclinical summaries, which are usually written by a toxicologist rather than the CMC author.

The draft asks for the Module 2 summary in 2.3.P.7 to be "a brief description and discussion of the CCS information for the drug product (see 3.2.P.7), with summary tables and hyperlinks to related testing reports." It asks for the same in 2.6.6.8, drawing on "leachables and extractables from 3.2.S.6, 3.2.P.2, and 3.2.P.7." In other words, the guidance expects the summaries to be built on cross-references that someone has checked. We have argued before that hyperlinks belong in the draft, not the publishing phase; this table is a good example of why.

Where the consistency problems come from

When the same facts appear in several places, they rarely disagree on purpose. They disagree because each section was written from a different source at a different point in development. The leachables study might name a component by supplier part number, the specification by its material, and the stability protocol by its pack size. A change of stopper supplier after the registration batches can reach 3.2.P.7 and miss 3.2.P.2.4. A toxicology assessment can be written against the extractables list from an earlier study.

This is the same problem we described for batch data in One Batch, a Dozen Tables: the difficulty is not writing each section, but keeping every section tied to the same underlying record. A useful exercise before filing is to take Table 4 as a checklist and confirm that each applicable section draws on consistent, traceable records for the relevant system, so that components, materials and studies are named the same way and at the same versions wherever they appear.

Points for generic manufacturers

The draft is not only about injectables and inhalers. Two passages apply directly to companies filing ANDAs for oral products.

The first is a caution against reusing a packaging justification: "It cannot be assumed that because a CCS was suitable for one drug product, it is automatically appropriate for another product." The draft adds that a system's leachables profile "can be affected by differences in manufacturing processes, variations in materials suppliers, or even subtle changes in the drug product's formulation." For a manufacturer using the same bottle and closure across a portfolio, the justification in each application has to be about that product.

The second is reassurance with a condition. For solid oral dosage forms, referencing the indirect food additive regulations and demonstrating compliance with the relevant USP standards "may be sufficient to establish safety and compatibility." But the draft also says that "low-risk dosage forms are not free of risk," and it flags exceptions such as hygroscopic excipients and the glycerin in softgel capsules. Oral solutions and suspensions with cosolvents may need more. The application should say why the product sits in the lower-risk group, not just that it does.

Many packaging suppliers hold Type III drug master files, and the draft confirms that a master file can carry the detailed material and suitability data. The application still needs a letter of authorisation and an exact reference, and the applicant's own sections still have to describe the system consistently with what the master file contains.

During development and after approval

For investigational applications, the draft keeps the phase-appropriate approach: brief descriptions early, more when the material or delivery system is novel. It adds that "updates to the CCS information should be provided if it differs from that reported in the studies for the previous phase." Packaging changes between phase 2 and phase 3 are common, and each one creates a small reconciliation task for the next IND amendment and, eventually, the marketing application.

After approval, the draft says the information in Table 4 "should also be included in supplements to report changes to approved applications," with risk analyses and quality data. A supplier change should therefore prompt a review of the sections it affects. Which reporting category applies, and what supporting data are needed, depend on the change and its risk.

The draft says FDA intends to follow it with topic-specific guidances on novel container closure systems and on extractables and leachables. Those will add detail to the testing. Table 4 offers a useful planning checklist, subject to revision in the final guidance, whether or not a comment went in by 13 October 2026.